A unique collection of 822 anticancer drugs for high throughput screening (HTS) and high content screening (HCS); Bioactivity and safety profiled in (confirmed by) pre-clinical and clinical settings (research and trials), an effective tool for molecular mechanism of tumorigenesis, and anti-tumor drug repositioning drug discovery; Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc; involved in 15 different cancer research areas, such as lung cancer, breast cancer, leukemia, lymphoma, etc. Detailed compound information with structure, target, activity, IC50 value, and biological activity description; Structurally diverse, medicinally active, and cell permeable; NMR and HPLC validated to ensure high purity and quality
